Loading
Led SIRIUS and the DREAMM programme, bringing daratumumab monotherapy and the BCMA ADC belantamab to myeloma.
Sagar Lonial led SIRIUS, the trial that won daratumumab its first approval as monotherapy in relapsed myeloma, and DREAMM-2, the pivotal trial of belantamab mafodotin, the first BCMA-directed ADC. He has led the Emory series showing near-universal deep responses to RVd induction and chairs the myeloma committee of the SWOG cooperative group.
| Title | Journal | Year |
|---|---|---|
| Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS) | Lancet | 2016 |
| Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2) | Lancet Oncology | 2020 |
Shares CD38, Monoclonal antibodies, Multiple myeloma and the tag myeloma.
Shares CD38, Monoclonal antibodies, Multiple myeloma and the tag myeloma.
Shares CD38, Monoclonal antibodies, Multiple myeloma and the tag myeloma.
Shares CD38, Monoclonal antibodies, Multiple myeloma and the tag myeloma.
Shares Belantamab mafodotin, Monoclonal antibodies, Multiple myeloma, Antibody-drug conjugate (ADC).
Shares CD38, BCMA, Multiple myeloma and the tag myeloma.
Shares BCMA, Multiple myeloma and the tag myeloma.
Shares CD38, Multiple myeloma and the tag myeloma.